Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.
Barbara
B
Faganel Kotnik
Vita
V
Dolzan
Iztok
I
Grabnar
Janez
J
Jazbec
D000293:Adolescent; D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D009994:Osmolar Concentration; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D058978:Reduced Folate Carrier Protein; D016896:Treatment Outcome; D055815:Young Adult
D026901:Membrane Transport Proteins; D058978:Reduced Folate Carrier Protein; C548699:SLC19A1 protein, human; D008727:Methotrexate